In this regard, recent trials evaluating the gut hormone glucagon-like peptide-1 (GLP-1) as well as specific GLP-1 receptor (GLP-1R) agonists for the treatment of T2D alone or T2D and obesity have shown promising results [5,6,7]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.